Experience with independent radiological review during a topotecan trial in ovarian cancer

被引:30
作者
Gwyther, S
Bolis, G
Gore, M
Huinink, WT
Verweij, J
Hudson, IR
Despax, R
JimenezLacave, A
机构
[1] UNIV MILAN,MILAN,ITALY
[2] ROYAL MARSDEN NHS TRUST,LONDON,ENGLAND
[3] NETHERLANDS CANC INST,AMSTERDAM,NETHERLANDS
[4] ROTTERDAM CANC INST,ROTTERDAM,NETHERLANDS
[5] UNIV ROTTERDAM HOSP,ROTTERDAM,NETHERLANDS
[6] SMITHKLINE BEECHAM PHARMACEUT LTD,HARLOW,ESSEX,ENGLAND
[7] CLIN PASTEUR,TOULOUSE,FRANCE
[8] UNIV OVIEDO,HOSP CENT ASTURIAS,E-33080 OVIEDO,SPAIN
关键词
independent radiological review; measurable disease; objective response rate; ovarian carcinoma; standard protocols;
D O I
10.1023/A:1008241127883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The results of phase II clinical trials are usually based on response of tumours to new oncolytic agents as evidenced by radiological imaging techniques. In this trial, all claimed responders were reviewed al a specially convened meeting by the peer group of study investigators and a radiologist, independent of the study institutions. Patients and methods: One hundred eleven patients with advanced epithelial ovarian cancer who had previously been treated with a platinum based regimen and had subsequently relapsed and who had measurable disease were treated with topotecan at a dose of 1.5 mg/m(2)/day i.v. on five consecutive days repeated every 21 days to assess efficacy and tolerability. Ninety-three were considered eligible for the study per protocol and lesions were assessed by either computerised tomography (CT) or ultrasound (US). At the meeting, scans from all 24 (25.8%) claimed responders were reviewed, lesions remeasured by the radiologist and a group discussion led I a final response classification. Results: Ninety-two patients were found to be eligible for the study and 14 (15.2%) were confirmed as responders, Ten were rejected as responders, mainly because the lesion did nor decrease in size by less than or equal to 50%, but one patient failed to meet the entry criteria, Remeasurement of CT scans was more objective than US scans. Difficulties were encountered during review of some CT scan sequences because of non uniform imaging parameters, Conclusions: Independent radiological review in conjunction with the peer review group in this trial enabled rigorous and consistent application of response criteria. This decreased the response rate from 25.8% to 15.2%, but this represents a more objective assessment. CT scanning is an objective technique for assessing response rates in phase II studies whereas US is subjective and dose not necessarily allow accurate lesion assessment on subsequent examinations, nor allows independent review at a later date. For these reasons it should not be used in such studies for accurate lesion assessment. Cross-sectional imaging techniques such as CT and magnetic resonance imaging (MRI) do allow accurate lesion assessment and independent review at a later date, but standard protocols need io be instituted, to allow consistency and a comparison to be made with subsequent studies using the same agent and a broad comparison to be made with other agents.
引用
收藏
页码:463 / 468
页数:6
相关论文
共 22 条
  • [1] Baker T. R., 1993, European Journal of Gynaecological Oncology, V14, P18
  • [2] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [3] ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE
    CARMICHAEL, J
    POSSINGER, K
    PHILLIP, P
    BEYKIRCH, M
    KERR, H
    WALLING, J
    HARRIS, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2731 - 2736
  • [4] TOPOISOMERASE-I INHIBITORS - TOPOTECAN AND IRENOTECAN
    CREEMERS, GJ
    LUND, B
    VERWEIJ, J
    [J]. CANCER TREATMENT REVIEWS, 1994, 20 (01) : 73 - 96
  • [5] EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION
    EISENHAUER, EA
    HUININK, WWT
    SWENERTON, KD
    GIANNI, L
    MYLES, J
    VANDERBURG, MEL
    KERR, I
    VERMORKEN, JB
    BUSER, K
    COLOMBO, N
    BACON, M
    SANTABARBARA, P
    ONETTO, N
    WINOGRAD, B
    CANETTA, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) : 2654 - 2666
  • [6] FUMOLEAU P, 1994, BREAST CANC RES TREA, V33, P39
  • [7] ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER
    HOSKINS, PJ
    SWENERTON, KD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 60 - 63
  • [8] DOCETAXEL IN ADVANCED OVARIAN-CANCER - PRELIMINARY-RESULTS FROM 3 PHASE-II TRIALS
    KAYE, SB
    PICCART, M
    AAPRO, M
    KAVANAGH, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : S14 - S17
  • [9] IFOSFAMIDE AND MESNA IN PREVIOUSLY TREATED ADVANCED EPITHELIAL OVARIAN-CANCER - ACTIVITY IN PLATINUM-RESISTANT DISEASE
    MARKMAN, M
    HAKES, T
    REICHMAN, B
    LEWIS, JL
    RUBIN, S
    JONES, W
    ALMADRONES, L
    PIZZUTO, F
    HOSKINS, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) : 243 - 248
  • [10] TAXOL - A UNIQUE ANTINEOPLASTIC AGENT WITH SIGNIFICANT ACTIVITY IN ADVANCED OVARIAN EPITHELIAL NEOPLASMS
    MCGUIRE, WP
    ROWINSKY, EK
    ROSENSHEIN, NB
    GRUMBINE, FC
    ETTINGER, DS
    ARMSTRONG, DK
    DONEHOWER, RC
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) : 273 - 279